Volume 4, Issue 1

MS, DMT & COVID 19 Vaccination

Editor's note:

With this issue we launch Volume 4 of eMultipleSclerosis Review. Our sincere thanks to our subscribers, readers, and listeners for your continued support. 

In this issue:

Is vaccination the best way for all patients with MS to protect themselves from COVID-19 infection? More than 20 MS DMTs are in current use. Which ones do not impact the effects of the vaccine and which diminish it? How should clinicians best advise their patients?  

These are some of the questions Dr. Joseph Sabatino from the Department of Neurology at the University of California San Francisco answers in this issue of eMultipleSclerosis Review. 

Learning objectives:

  • Explain the effects of different MS DMTs on SARS-CoV-2 vaccine-elicited antibody and T cell immunity.
  • Describe factors that contribute to the likelihood of generating a SARS-CoV-2 vaccine antibody response in patients on anti-CD20 monoclonal antibody therapies.

Author:

Joseph Sabatino, Jr., MD, PhD
Joseph Sabatino, Jr., MD, PhD

Assistant Adjunct Professor, Department of Neurology
University of California San Francisco
San Francisco, CA

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: November 19, 2021
Expiration date: November 18, 2023